Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Marinus Pharma
(NASDAQ:MRNS)
Intraday
$9.04
0.19
[2.15%]
After-Hours
$9.04
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$9.04
0.19
[2.15%]
At close: Mar 28
$9.04
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Marinus Pharma Stock (NASDAQ:MRNS)
Marinus Pharma Stock (NASDAQ: MRNS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 27, 2024
Marinus Pharmaceuticals Comments On Ovid Therapeutics' Patent Challenge And Provides Update On Marinus' Post Grant Review
Benzinga Newsdesk
-
1 day ago
Tuesday, March 26, 2024
Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights
Benzinga Insights
-
2 days ago
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Benzinga Newsdesk
-
2 days ago
Thursday, March 07, 2024
The Medicines And Healthcare Products Regulatory Agency Has Approved The Medicine Ganaxolone As The First Anti-Seizure Medication In The UK To Treat Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
Benzinga Newsdesk
-
Mar 7, 2024, 12:39PM
Oppenheimer Maintains Perform on Marinus Pharma, Maintains $9 Price Target
Benzinga Newsdesk
-
Mar 7, 2024, 8:04AM
Wednesday, March 06, 2024
RBC Capital Reiterates Outperform on Marinus Pharma, Maintains $24 Price Target
Benzinga Newsdesk
-
Mar 6, 2024, 10:13AM
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Benzinga Newsdesk
-
Mar 6, 2024, 7:38AM
Tuesday, March 05, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Mar 5, 2024, 4:31PM
Leverage Shares -3x Short Moderna (MRNA) ETP Securities: Q4 Earnings Insights
Benzinga Insights
-
Mar 5, 2024, 4:25PM
Marinus Pharma Q4 2023 GAAP EPS $(0.740) Misses $(0.630) Estimate, Sales $7.190M Miss $8.015M Estimate
Benzinga Newsdesk
-
Mar 5, 2024, 4:23PM
Earnings Scheduled For March 5, 2024
Benzinga Insights
-
Mar 5, 2024, 5:00AM
Monday, March 04, 2024
Marinus Pharma's Earnings Outlook
Benzinga Insights
-
Mar 4, 2024, 11:02AM
Thursday, February 08, 2024
Marinus Pharmaceuticals 13G Filing Shows Jennison Associates LLC Reported A 5.4% Stake In The Co As Of December 31, 2023
Benzinga Newsdesk
-
Feb 8, 2024, 2:00PM
Thursday, January 04, 2024
Marinus Pharmaceuticals Projects Fy24 U.S. Ztalmy Net Product Revenue Of $32M-$34M
Benzinga Newsdesk
-
Jan 4, 2024, 7:09AM
Marinus Pharmaceuticals Sees FY23 Ztalmy (Ganaxolone) Revenues Of $19.5M-$19.7M, With Q4 Ztalmy Revenues Of $6.5M-$6.7M
Benzinga Newsdesk
-
Jan 4, 2024, 7:08AM
Tuesday, December 05, 2023
Analyst Expectations for Marinus Pharma's Future
Benzinga Insights
-
Dec 5, 2023, 1:00PM
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Benzinga Newsdesk
-
Dec 5, 2023, 6:45AM
Wednesday, November 22, 2023
Marinus Pharmaceuticals, Inc. Awarded $3.2M Department Of Veterans Affairs Contract For Drugs And Biologicals Pharmaceutical Preparation Manufacturing
Benzinga Newsdesk
-
Nov 22, 2023, 11:48AM
Monday, November 20, 2023
Marinus Pharmaceuticals Reports Seven Presentations At AES 2023, New Publication In Epilepsia And Results From Second Generation Formulation MAD Study
Benzinga Newsdesk
-
Nov 20, 2023, 4:05PM
Wednesday, November 08, 2023
Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $25-Report Released on 7th Nov
Benzinga Newsdesk
-
Nov 8, 2023, 10:42AM
Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $25
Benzinga Newsdesk
-
Nov 8, 2023, 10:11AM
Tuesday, November 07, 2023
Marinus Pharmaceuticals Now Expects 2023 ZTALMY Net Product Revenues Of $18.5M-$19M Vs Previous Guidance Of $17M-$18.5M; Cash Runway Projected Into Q4 2024
Benzinga Newsdesk
-
Nov 7, 2023, 7:15AM
Marinus Pharmaceuticals Initiates Global Access Program For ZTALMY (ganaxolone) Oral Suspension CV
Benzinga Newsdesk
-
Nov 7, 2023, 7:09AM
Marinus Pharma Q3 EPS $(0.61) Vs $1.89 Last Year, Sales $7.34M Beat $6.33M Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 7:08AM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Thursday, September 21, 2023
Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target
Benzinga Newsdesk
-
Sep 21, 2023, 9:06AM
Wednesday, September 20, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Sep 20, 2023, 5:31PM
Analyst Ratings for Marinus Pharma
Benzinga Insights
-
Sep 20, 2023, 10:01AM
RBC Capital Maintains Outperform on Marinus Pharma, Raises Price Target to $21
Benzinga Newsdesk
-
Sep 20, 2023, 9:35AM
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Benzinga Newsdesk
-
Sep 20, 2023, 6:35AM
Tuesday, September 19, 2023
Marinus Pharmaceuticals shares are trading higher after the company issued guidance and said RAISE trial enrollment trends have returned to anticipated levels.
Benzinga Newsdesk
-
Sep 19, 2023, 1:45PM
Marinus Pharmaceuticals Says Cash Runway Now Expected Into Q4 2024 With Projected Cash, Cash Equivalents And Short-term Investments Of Between $170M-$175M As Of September 30, 2023
Benzinga Newsdesk
-
Sep 19, 2023, 8:18AM
Marinus Pharmaceuticals Expects Q3 2023 Ztalmy (Ganaxolone) Net Product Revenues Of Around $5M-$5.2M; On Track To Meet FY23 Expected Ztalmy Revenues Of $17M-$18.5M
Benzinga Newsdesk
-
Sep 19, 2023, 8:16AM
Marinus Pharmaceuticals Says Enrollment Trends In The RAISE Trial For Intravenous Ganaxolone In Refractory Status Epilepticus Have Returned To Anticipated Levels; On Track For Topline Data In Q1 Of 2024
Benzinga Newsdesk
-
Sep 19, 2023, 8:14AM
Monday, August 21, 2023
Marinus Pharmaceuticals Said On August 17, The PTAB Granted Co's Petition Seeking Post-grant Review Of Ovid Therapeutics' U.S. Patent No. 11,395,817
Charles Gross
-
Aug 21, 2023, 7:05AM
Friday, August 11, 2023
Marinus Pharmaceuticals shares are trading lower after Oppenheimer downgraded the stock from Outperform to Perform and announced a $14 price target. Additionally, multiple firms lowered their respective price targets on the stock.
Benzinga Newsdesk
-
Aug 11, 2023, 3:27PM
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Aug 11, 2023, 1:47PM
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Benzinga Newsdesk
-
Aug 11, 2023, 12:59PM
RBC Capital Maintains Outperform on Marinus Pharma, Lowers Price Target to $20
Benzinga Newsdesk
-
Aug 11, 2023, 12:05PM
Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $32
Benzinga Newsdesk
-
Aug 11, 2023, 11:56AM
Ladenburg Thalmann Maintains Buy on Marinus Pharma, Lowers Price Target to $13
Benzinga Newsdesk
-
Aug 11, 2023, 11:17AM
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
Benzinga Insights
-
Aug 11, 2023, 11:00AM
Analyst Ratings for Marinus Pharma
Benzinga Insights
-
Aug 11, 2023, 8:00AM
Baird Maintains Outperform on Marinus Pharma, Lowers Price Target to $20
Benzinga Newsdesk
-
Aug 11, 2023, 7:56AM
Oppenheimer Downgrades Marinus Pharma to Perform, Announces $14 Price Target
Benzinga Newsdesk
-
Aug 11, 2023, 4:42AM
Thursday, August 10, 2023
Marinus Pharma Raised FY23 Outlook: ZTALMY Revenue $17M-$18.5M From $15M-$17M, BARDA Revenue $11M-$12M From $8M-$11M
Benzinga Newsdesk
-
Aug 10, 2023, 7:08AM
Marinus Pharma Q2 EPS $(0.61) Beats $(0.72) Estimate, Sales $6.08M Beat $5.73M Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 7:03AM
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Wednesday, August 09, 2023
Earnings Preview: Marinus Pharma
Benzinga Insights
-
Aug 9, 2023, 12:01PM
Monday, July 31, 2023
The European Commission Has Approved Marinus Pharmaceuticals' Ztalmy (Ganaxolone) Oral Suspension For The Adjunctive Treatment Of Epileptic Seizures Associated With Cyclin-dependent Kinase-like 5 Deficiency Disorder In Patients Two To 17 Years
Benzinga Newsdesk
-
Jul 31, 2023, 7:14AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch